Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 3, 2005, Pages 1288-1297

  Bourdet, David L ^a   Pritchard, John B ^b   Thakker, Dhiren R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISOPROTEIN; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; QUINIDINE; RANITIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG POTENCY; DRUG UPTAKE; ELECTROPHYSIOLOGY; FEMALE; IC 50; INTESTINE; LIVER; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS LAEVIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FAMOTIDINE; HUMANS; MICROINJECTIONS; MOLECULAR STRUCTURE; OOCYTES; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; POLYMERASE CHAIN REACTION; RANITIDINE; SUBSTRATE SPECIFICITY; XENOPUS LAEVIS;

EID: 27744570434     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.091223     Document Type: Article

References (38)

1. Aslamkhan A, Han YH, Walden R, Sweet DH, and Pritchard JB (2003) Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol 285:F775-F783.
2. Bleasby K, Chauhan S, and Brown CD (2000) Characterization of MPP+ secretion across human intestinal Caco-2 cell monolayers: role of P-glycoprotein and a novel Na(+)-dependent organic cation transport mechanism. Br J Pharmacol 129:619-625.
3. Boom SP, Meyer I, Wouterse AC, and Russel FG (1998) A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. Biopharm Drug Dispos 19:199-208.
4. Bourdet DL and Thakker DR (2003) Evidence for carrier-mediated apical uptake of ranitidine in Caco-2 cells (Abstract). AAPS PharmSci 5:R6056.
5. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, and Koepsell H (1996) Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem 271:32599-32604.
6. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
7. Dresser MJ, Xiao G, Leabman MK, Gray AT, and Giacomini KM (2002) Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res (NY) 19:1244-1247.
8. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881.
9. Gramatte T, el Desoky E, and Klotz U (1994) Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 46:253-259.
10. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, and Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature (Lond) 372:549-552.
11. Hayer-Zillgen M, Bruss M, and Bonisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829-836.
12. Hughes CM, Swanton JG, and Collier PS (1995) The effect of three H2 receptor antagonists on the disposition of cyclosporin A in the in situ perfused rat liver model. Biopharm Drug Dispos 16:719-733.
13. Inotsume N, Nishimura M, Nakano M, Fujiyama S, and Sato T (1990) The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol 30:50-56.
14. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, and Ganapathy V (1998) Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273:15971-15979.
15. Klotz U, Arvela P, and Rosenkranz B (1985) Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol 28:671-675.
16. Klotz U and Walker S (1990) Biliary excretion of H2-receptor antagonists. Eur J Clin Pharmacol 39:91-92.
17. Kroemer H and Klotz U (1987) Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 25:458-463.
18. Lee K, Ng C, Brouwer KLR, and Thakker DR (2002) Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J Pharmacol Exp Ther 303:574-580.
19. Lee K and Thakker DR (1999) Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 88:680-687.
20. Lin JH (1991) Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 20:218-236.
21. Martel F, Grundemann D, Calhau C, and Schomig E (2001) Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn-Schmiedeberg's Arch Pharmacol 363:40-49.
22. McNeil JJ, Mihaly GW, Anderson A, Marshall AW, Smallwood RA, and Louis WJ (1981) Pharmacokinetics of the H2-receptor antagonist ranitidine in man. Br J Clin Pharmacol 12:411-415.
23. Mihaly GW, Smallwood RA, Anderson JD, Jones DB, Webster LK, and Vajda FJ (1982) H2-receptor antagonists and hepatic drug disposition. Hepatology 2:828-831.
24. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
25. Motohashi H, Uwai Y, Hiramoto K, Okuda M, and Inui K (2004) Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol 503:25-30.
26. Muirhead M, Bochner F, and Somogyi A (1988) Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. J Pharmacol Exp Ther 244:734-739.
27. Nagata Y, Kusuhara H, Hirono S, Endou H, and Sugiyama Y (2004) Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. Drug Metab Dispos 32:1040-1047.
28. Ng C, Thakker DR, and Brouwer KL (2002) Localization and expression of hOCT1 in Caco-2 cell monolayers (Abstract). AAPS PharmSci 4:T2207.
29. Smith SR and Kendall MJ (1988) Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 15:44-56.
30. Somogyi A and Bochner F (1984) Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol 18:175-181.
31. Suttle AB and Brouwer KL (1994) Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat. Drug Metab Dispos 22:224-232.
32. Urakami Y, Akazawa M, Saito H, Okuda M, and Inui K (2002) cDNA cloning, functional characterization and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13:1703-1710.
33. van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, and de Schepper PJ (1982) Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol 14:195-200.
34. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, and Ganapathy V (2000) Structure, function and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol 279:F449-F458.
35. Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, and Williams RL (1987) Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm Drug Dispos 8:549-560.
36. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.
37. Zhang L, Gorset W, Dresser MJ, and Giacomini KM (1999) The interaction of N-tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol Exp Ther 288:1192-1198.
38. Zhang L, Schaner ME, and Giacomini KM (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286:354-361.